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Abstract 
Background and Aim: Few studies of zinc monotherapy for presymptomatic Wilson disease 
have focused on young children. We therefore evaluated long-term efficacy and safety of zinc 
monotherapy for such children, and established benchmarks for maintenance therapy. 
Methods: We retrospectively and prospectively examined children under 10 years old with 
presymptomatic Wilson disease who received zinc monotherapy from time of diagnosis at 12 
participating pediatric centers in Japan. 
Results: Twenty-four patients met entry criteria. Aspartate aminotransferase and alanine 
aminotransferase decreased significantly beginning 1 month after initiation of treatment and 
usually remained under 50 U/L from 1 to 8 years of treatment. Twenty four-hour urinary 
copper decreased significantly at 6 months, and usually remained under 75 μg/day and 
between 1 and 3 μg/kg/day for the remainder of the study. All patients continued to take zinc, 
and none became symptomatic. In patients under 6 years old who received 50 mg/day of zinc 
as an initial dose, aspartate aminotransferase and alanine aminotransferase significantly 
decreased at 1 month after initiation of treatment, as did γ-glutamyltransferase and 24-hour 
3 
 
urinary copper at 6 months. 
Conclusions: To our knowledge, this is the first multicenter study of zinc monotherapy for 
young children with presymptomatic Wilson disease. Such monotherapy proved highly 
effective and safe. Maintaining normal transaminase values (or values under 50 U/L when 
normalization is difficult) and 24-h urinary copper excretion between 1 and 3 μg/kg/day and 
under 75 μg/day is a reasonable goal. An initial dose of 50 mg/day is appropriate for patients 
under 6 years old. 
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Introduction 
Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by 
mutations in the ATP7B gene leading to copper accumulation in hepatocytes and in 
extrahepatic organs such as the brain and kidney. The phenotype of WD is designated by the 
major symptomatic organ (if any), such as "hepatic type," "neurologic type," and 
"presymptomatic type." The American Association for the Study of Liver Diseases (AASLD) 
and the European Association for the Study of the Liver (EASL) guidelines recommend zinc 
monotherapy as treatment for presymptomatic patients with WD as well as those with 
neurologic WD.1,2 In Japan, zinc acetate was accepted as therapy by the Ministry of Health, 
Labor, and Welfare in 2008. Zinc monotherapy is effective for presymptomatic WD, as is 
D-penicillamine.3 Additionally, some reports indicate that zinc monotherapy is safer for 
children with presymptomatic WD than D-penicillamine.4 However, most previous reports 
describe zinc monotherapy for adults and for children over 10 years old,5-7 with less 
investigation of young children with presymptomatic WD.8-10 Some previous reports 
recommended that patients taking zinc should maintain 24-h urinary copper excretion values 
under 75 to 100 μg/day,1,2 which may represent insufficient reduction of copper in the body in 
treating young children with presymptomatic WD. We previously suggested that a reasonable 
goal in treating young presymptomatic children with WD using zinc would be maintaining 
24-h urinary copper excretion between 1 and 3 μg/kg/day for the first 1 to 2 years.10 
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 The AASLD and EASL guidelines recommend initial zinc doses of 150 mg/day for larger 
children and adults and 75 mg/day for smaller children (below 50 kg in body weight).1,2 On 
the other hand, Brewer et al. and Shimizu et al. recommend an initial zinc dose of 50 mg/day 
for patients 1 to 5 years old and 75 mg/day for those 6 to 15 years old.11,12 However, we know 
of no reports focusing on the effects of 50 mg/day as an initial dose of zinc for 1- to 
5-year-old patients. 
 We therefore evaluated long-term efficacy and safety of zinc monotherapy for children under 
10 years old with presymptomatic WD at Japanese pediatric centers, aiming to establish 
appropriate benchmarks for maintenance therapy. We also clarified the effect of zinc at the 
initial dose of 50 mg/day given to patients under 6 years old. 
 
Patients and Methods 
Between 2008 and 2016, at 12 participating pediatric centers in Japan, we retrospectively and 
prospectively examined young children under 10 years old with presymptomatic WD who 
satisfied diagnostic criteria according to the Leipzig score (≥ 4).1,13 Presymptomatic patients 
are diagnosed before developing clinical manifestations of WD such as jaundice, 
hepatomegaly, or neurologic abnormalities--usually as a result of family screening. 
Occasionally, they are identified when results of routine blood tests obtained while treating 
respiratory infections or enteritis include elevated serum transaminases.1,2,11 We included only 
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patients treated with zinc monotherapy from time of diagnosis. We monitored serum aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (GGT), free 
copper (non-ceruloplasmin-bound copper = total copper - ceruloplasmin x 3.15), and 24-h 
urinary copper before and after initiation of zinc monotherapy. Additional laboratory 
monitoring included white blood cell count, hemoglobin, platelet count, serum total bilirubin, 
albumin, iron, amylase, lipase, zinc, and prothrombin time, as well as 24-h urinary zinc 
excretion. Additionally, we performed abdominal ultrasonograpy and evaluated clinical WD 
manifestations, drug compliance, and adverse effects of zinc. The prescribed initial dose of 
zinc acetate for patients under 6 years old was 50 mg/day; for those 6 years or older, this dose 
was 75 mg/day.11,12 We increased the dose of zinc if patients showed ALT elevation to more 
than twice the upper limit of normal, and decreased it if they showed adverse effects of zinc 
such as iron-deficiency anemia or pancytopenia. We evaluated patient compliance with zinc 
monotherapy by interview and by laboratory values for serum and urinary zinc, excluding 
patients poorly compliant with zinc monotherapy from the study (those suspected to have 
taken under 70% of prescribed doses). 
 To evaluate the effect of zinc at the initial dose of 50 mg/day given to patients under 6 years 
old, laboratory values including AST, ALT, GGT, and 24-h urinary copper were examined in 
these patients for the first 6 months after initiation of treatment. 
 The study protocol complied with the ethical guidelines of the Declaration of Helsinki of 
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1975 (2004 revision) and was approved by the Ethics Committee of Kurume University and 
other participating centers. 
 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD) and categorical 
variables as frequency; ranges are given in some instances. Statistical analyses were 
performed using Student’s t test, analyses of variance (ANOVA), or a Tukey-Kramer test as 
appropriate. All statistical analysis was performed using GRAPHPAD PRISM version 6.05 
software (GraphPad Software, San Diego, CA, USA). Tests were two- sided, and P values 
below 0.05 were considered to indicate statistical significance. 
 
Results 
Patient characteristics and laboratory findings at time of diagnosis 
Twenty-four patients were enrolled in this study; 13 were girls. Mean age and mean body 
weight at diagnosis were 6.1 years (range, 3 to 9) and 21.8 kg (range, 15.6 to 34.0), 
respectively. Five patients were diagnosed by family screening, while 19 others were found to 
have unexpected laboratory abnormalities such as AST and ALT elevations when evaluated 
for respiratory infection or enteritis. The mean follow up period was 3.8 years (range, 0.5 to 
8). No patient had a Kayser-Fleischer ring or had brain abnormalities detected by magnetic 
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resonance imaging (Table 1). At time of diagnosis, AST/ALT, GGT and 24-hour urinary 
copper were 153 ± 115/243 ± 151 U/L (mean ± SD), 98 ± 69 U/L and 118 ± 50 μg/day (5.5 ± 
2.7 μg/kg/day), respectively (Table 2). 
 
Course of clinical and laboratory values before and after initiation of zinc monotherapy 
AST/ALT significantly decreased to 49 ± 13/70 ± 29 U/L (P<0.05) at only 1 month after 
initiation of treatment; these mostly remained under 50 U/L between 1 and 8 years (AST/ALT, 
34 ± 6/40 ± 18 and 26 ±2 /30 ± 5 U/L at 1 and 8 years of treatment, respectively). Proportions 
of patients with normal values for both AST and ALT (≤ 30 U/L) were 18%, 41%, and 75% at 
1, 2, and 8 years of treatment, respectively. GGT significantly decreased to 57 ± 49 U/L 
(P<0.05) at only 1 month and remained nearly normal between 1 and 8 years of treatment 
(Fig. 1a-c). Twenty four-hour urinary copper significantly decreased to 47 ± 19 μg/day (2.2 ± 
1.0 μg/kg/day; P<0.05) at 6 months and been mostly remained under 75 μg/day and between 
1 and 3 μg/kg/day for the remainder of the study (2.2 ± 0.6 and 1.4 ± 0.2 μg/kg/day at 1 and 8 
years, respectively; Fig. 2a,b). Serum free copper was nearly normal during the follow-up 
period (Table 2 and Fig. 1d). Serum total bilirubin and amylase were normal and did not show 
significant change (Table 2 and Fig. S1A,B). Serum zinc significantly increased to 210 ± 80 
μg/dL (P<0.05) at 1 month after initiation of treatment (Fig. S1C). All patients continued to 
take zinc without any evidence of toxicity or need for other drugs such as D-penicillamine or 
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trientine, although some patients needed to increase the amount of zinc to doses of 75 to 150 
mg/day during the follow-up period. None of our 24 patients became clinically symptomatic. 
 
Course of laboratory values in patients under 6 years old with initial dose of zinc 50 mg/day 
for the first 6 months 
Eleven patients were diagnosed when under 6 years old; 7 were girls. Mean age and mean 
body weight at diagnosis were 4.5 years and 17.7 kg, respectively. At time of diagnosis, 
AST/ALT, GGT and 24-h urinary copper were 165 ± 157/220 ± 193 U/L, 81 ± 70 U/L, and 
105 ± 60 μg/day (6.0 ± 3.7 μg/kg/day), respectively. All of these patients received an initial 
zinc dose of 50 mg/day during the first 6 months of follow-up. AST/ALT significantly 
decreased to 49 ± 13/65 ± 32 U/L at only 1 month after initiation of treatment. GGT and 24-h 
urinary copper significantly decreased to 23 ± 13 U/L and 43 ± 22 μg/day (2.3 ± 1.2 
μg/kg/day) at 6 months after initiation of treatment, respectively (Fig. 3). 
 
Discussion 
To evaluate long-term efficacy and safety of zinc monotherapy for young children with 
presymptomatic WD, we retrospectively and prospectively examined 24 patients at 12 
participating pediatric centers in Japan. Long-term zinc monotherapy for young children with 
presymptomatic WD proved highly effective and safe. An initial dose of zinc 50 mg/day was 
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effective for patients under 6 years old.  
 While AASLD and EASL guidelines recommend zinc monotherapy as a treatment for 
presymptomatic patients with WD,1,2 other drugs also are available for the treatment of WD in 
Japan, including D-penicillamine and trientine. All three drugs are fully efficacious when 
taken properly, and will remove excess copper and prevent its reaccumulation. Side effects of 
zinc such as gastrointestinal symptoms have developed in about 54% of patients treated for 
WD, but these side effects were considered mild in all patients and of little consequence.5,12 
Zinc is effective and safe for children with presymptomatic WD,8-10,14 and effectiveness of 
long-term treatment with D-penicillamine versus zinc was similar in patients who were able 
to continue the initial therapy.6 On the other hand, zinc has been reported to remove copper 
more slowly than the other drugs.15 
 As most previous studies of zinc monotherapy have concerned adults or children over 10 
years old,5-7 we presently evaluated zinc monotherapy in children with presymptomatic WD 
who were under 10 years old, aiming to complement the few existing reports of young 
children.8-10 Our report also describes a multicenter investigation, while the previous reports 
of young children were single-center studies.8-10 All patients continued to take zinc without 
any evidence of zinc toxicity or need for additional drugs such as D-penicillamine or trientine. 
None of our 24 patients became clinically symptomatic. These results indicate that long-term 
zinc monotherapy for young children with presymptomatic WD is highly effective and safe. 
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 Chelating agents rapidly decrease free copper concentrations by the formation of excretable 
complexes, while zinc primarily reduces the intestinal absorption of copper. In the liver, zinc 
also induces activity of metallothionein, which sequesters excessive copper, contributing to a 
mild negative copper balance.3,16 
 In all patients, the duration of initial therapy depends upon the drug being used, representing 
about 2 months with D-penicillamine or trientine and about 4 to 6 months with zinc 
monotherapy.15 However, in single-center studies, Mizuochi et al. and Abuduxikuer et al. 
reported that zinc monotherapy for children with presymptomatic WD significantly decreased 
AST and ALT in 1 month after initiation of zinc and reduced 24-h urinary copper excretion 
over 6 to 8 months.8,10 In our multicenter study, AST and ALT significantly decreased, most 
often to under 100 U/L, at 1 month after initiation of zinc. Additionally, 24-h urinary copper 
had significantly decreased, usually to under 75 μg/day, at 6 months after initiation of zinc. 
These results indicate that zinc monotherapy for young children with presymptomatic WD 
could reverse copper accumulation somewhat faster than previously reported. 
 The AASLD and EASL guidelines recommend that all patients with WD taking zinc should 
maintain 24-h urinary copper excretion values under 75 to 100 μg/day.1,2 However, this goal 
may be insufficient in treating presymptomatic young children with WD. We previously 
reported that zinc treatment in such children should aim to maintain 24-h urinary copper 
excretion between 1 and 3 μg/kg/day for the first 1 to 2 years.10 Serum free copper also can be 
12 
 
used to monitor zinc efficacy. Brewer et al. reported that a serum free copper value of 25 
μg/dL or less can be considered a reasonable goal in adults undergoing zinc treatment.17 Zinc 
therapy in children with WD also caused statistically significant reduction of serum free 
copper from pretreatment values at 1 year after initiation of zinc.14 In this multicenter study, 
we maintained AST/ALT under 50 U/L and 24-h urinary copper under 75 μg/day and between 
1 and 3 μg/kg/day for 1 to 8 years. None of our 24 patients became clinically symptomatic or 
had severe side effects from zinc. However, most serum free copper values were within the 
normal range, with no signifficant differences noted throughout the follow-up period. 
Considering pertinent results together, we suggest that a reasonable goal in treating young 
children with presymptomatic WD using zinc would be maintaining both transaminases at 
normal values (or values under 50 U/L if normalization is difficult) and 24-h urinary copper 
excretion under 75 μg/day and between 1 and 3 μg/kg/day. A previous report made the point 
that some patients with WD have normal values of serum free copper before treatment,18 and 
in our study most patients had normal values during the follow-up period. Serum free copper 
may be insufficiently sensitive for monitoring zinc efficacy in young children with 
presymptomatic WD. 
 The AASLD and EASL recommendations include an initial zinc dose of 75 mg/day for 
smaller children (under 50 kg in body weight).1,2 On the other hand, Brewer et al. and 
Shimizu et al. reported use of initial doses of zinc of 50 mg/day for 1- to 5-year-old patients 
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and 75 mg/day for 6- to 15-year-olds.11,12 However, we know of no reports focusing on the 
effects of 50 mg/day as an initial dose of zinc for 1- to 5-year-old patients. In the present study, 
we examined laboratory values in patients under 6 years old who received 50 mg/day of zinc 
as an initial dose for the first 6 months of treatment. AST and ALT significantly decreased at 1 
month after initiation of treatment, as did GGT and 24-h urinary copper at 6 months after 
initiation. These results indicate that an initial dose of zinc with 50 mg/day seems to be an 
appropriate dose for under 6-year-old patients with presymptomatic WD. 
 An important limitation of this study is the retrospective nature of data collection in most 
patients. As a consequence, data were acquired out at different times in individual patients. 
Further, the number of patients was small. A larger, more long-term prospective study would 
be desirable. 
 In conclusion, we believe this study to be the first multicenter evaluation of zinc 
monotherapy for young children with presymptomatic WD. Long-term zinc monotherapy for 
young children with presymptomatic WD is highly effective and safe. A reasonable goal in 
treating young children with presymptomatic WD using zinc appears to be maintaining both 
normal transaminase values (or values under 50 U/L if normalization is difficult) and 24-h 
urinary copper excretion between 1 and 3 μg/kg/day, as well as under 75 μg/day. An initial 
zinc dose of 50 mg/day is appropriate for patients under 6 years old with presymptomatic 
WD. 
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Figure legends 
Figure 1. Course of blood test results before and after zinc monotherapy.  
(a) aspartate aminotransferase (AST), (b) alanine aminotransferase (ALT), (c) 
γ-glutamyltransferase (GGT) and (d) serum free copper. *, P < 0.05 versus Pre, **, P < 0.01 
versus Pre; ***, P < 0.001 versus Pre. mo, month(s) after initiation of zinc therapy; n, number 
of patient at each time points; Pre, pretreatment; SD, standard deviation; y, year(s) after 
initiation of zinc therapy. 
 
Figure 2. Course of urine test results before and after zinc monotherapy.  
(a) 24-h urinary copper and (b) 24-h urinary copper per weight. *, P < 0.05 versus Pre; **, P 
< 0.01 versus Pre; ***, P < 0.001 versus Pre. mo, month(s) after initiation of zinc therapy; n, 
number of patient at each time points; Pre, pretreatment; SD, standard deviation; y, year(s) 
after initiation of zinc therapy. 
  
Figure 3. Course of laboratory results before and after zinc monotherapy in patients 
under 6 years old receiving a 50 mg/day dose.  
(a) aspartate aminotransferase (AST), (b) alanine aminotransferase (ALT), (c) 
γ-glutamyltransferase (GGT), (d) 24-h urinary copper, and (e) 24-h urinary copper per weight. 
*, P < 0.05 vs. Pre, **, P < 0.01 vs. Pre. mo, month(s) after initiation of zinc therapy; n, 
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number of patient at each time points; Pre, pretreatment; SD, standard deviation. 
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Table 1. Patient characteristics at time of diagnosis (n=24) 
Gender (male/female) 11/13 
Age, years, mean (range) 6.1 (3–9) 
Body weight, kg, mean (range) 21.8 (15.6–34.0) 
Diagnosis suspected from 
 
    Unexpected laboratory abnormalities 19 
    Family screening 5 
Follow up period, years, mean (range) 3.8 (0.5–8) 
Kayser-Fleischer ring 0 
Brain MRI abnormalities 0 
MRI, magnetic resonance imaging; n, number of patients. 
 
Table 2. Laboratory findings at time of diagnosis 
    mean ± SD reference range 
AST (n=24) (U/L) 153 ± 115 13–30 
ALT (n=24) (U/L) 243 ± 151 7–30 
GGT (n=23) (U/L) 98 ± 69 9–32 
Total bilirubin (n=22) (mg/dL) 0.6 ± 0.2 0.4–1.2 
Serum ceruloplasmin (n=24) (mg/dL) 5.6 ± 4.9 20–40 
Serum free copper (n=24) (µg/dL) 10.5 ± 7.6 <15 
Urinary copper (n=20) 
(µg/day) 118 ± 50 13–33 
(µg/kg/day) 5.5 ± 2.7 unknown 
AST, aspartate aminotransferase; ALT alanine aminotransferase: GGT, γ-glutamyltransferase; 
n, number of patients; SD, standard deviation. 
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